echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur Arch Otorhinolaryngol: Long-term Hearing Follow-up of Pediatric Platinum-Induced Ototoxicity

    Eur Arch Otorhinolaryngol: Long-term Hearing Follow-up of Pediatric Platinum-Induced Ototoxicity

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The platinum drugs cisplatin and carboplatin are widely used to treat several childhood and adolescent malignancies, including neuroblastoma, osteosarcoma, germ cell tumor, teratoma, hepatoblastoma, and various brain tumors (gliomas).
    , astrocytoma, medulloblastoma)
    .

    Irreversible bilateral sensorineural hearing loss is a common side effect of platinum compounds
    .


    Long-term hearing monitoring and management of hearing impairment are emerging concerns in pediatric oncology due to improved overall survival


    Researchers from Italy, published in Eur Arch Otorhinolaryngol, conducted long-term hearing follow-up of pediatric platinum-induced ototoxicity Hearing follow-up

    The study was a retrospective observational design
    .


    Between 2007 and 2014, 38 of the 116 children who received chemotherapy (cisplatin and/or carboplatin) and/or radiation at the investigator's institution were recruited


    At the end of the 5-year follow-up, there was a significant increase in ototoxicity compared with that observed at the end of chemotherapy (52.
    5% vs 39.
    5%, P<0.
    001)
    .


    Late-onset hearing loss occurred in 13.


    Distribution of hearing loss at end of follow-up

    Distribution of hearing loss at end of follow-up

    In conclusion, long-term monitoring of at least 5 years may prevent the deleterious effects of hearing deprivation following platinum-based chemotherapy in children


    Long-term monitoring for at least 5 years can prevent harmful effects of hearing deprivation after platinum-based chemotherapy in children Long-term monitoring for at least 5 years can prevent harmful effects of hearing deprivation after platinum-based chemotherapy in children

    Original source:

    Original Source: Original Source:

    Anna Rita Fetoni, Francesca Brigato, Eugenio De Corso et al.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.